Immuneering reports 17.3-month survival data for pancreatic cancer drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Oppenheimer Reiterates Outperform Rating on Immuneering Corporation (IMRX) Following Data
June 1, 2026 9:59 AM EDTOppenheimer analyst Jay Olson reiterated an Outperform rating and $30.00 price target on Immuneering Corporation (NASDAQ: IMRX) after the company reported 17.3-month survival data for pancreatic cancer drug/
The analyst commented, "Following RVMD's presentation of details from the RASolute-302 study during a plenary session at... More
